Загрузка...

Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status

Lorlatinib treatment should be positively considered even for patients with ALK‐positive NSCLC with severe neurocognitive disturbance and poor performance status due to CNS metastases, including leptomeningeal carcinomatosis.

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Case Rep
Главные авторы: Taketa, Tomoyo, Nakamura, Takahito
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2021
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8077276/
https://ncbi.nlm.nih.gov/pubmed/33936630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.3927
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!